Answers are grounded in this paper and cite their sources.
Case reports reveal secondary hematologic malignancies after chemotherapy for bladder cancer, indicating potential risks.
Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C. In one patient, karyotypic abnormalities (-5, 7q-) typical of a therapy induced malignancy were associated with rapid progression of a refractory anemia with excess blasts in transformation to an acute non-lymphocytic leukemia. Intravesical chemotherapy may be associated with a risk of secondary malignancy
No takes yet. Share an insight, caveat, or question.
Sonneveld et al. (1990) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: